FibroGen (NASDAQ:FGEN) Releases Earnings Results, Beats Expectations By $2.40 EPS

FibroGen (NASDAQ:FGEN) released its earnings results on Monday. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, beating the consensus estimate of ($4.01) by $2.40, Zacks reports.

FibroGen Trading Down 0.3%

FGEN stock traded down $0.03 during trading on Monday, reaching $11.00. 42,197 shares of the stock were exchanged, compared to its average volume of 68,750. The firm has a market capitalization of $44.48 million, a price-to-earnings ratio of -28.95 and a beta of 0.75. The business has a 50 day moving average price of $11.42 and a 200-day moving average price of $9.02. FibroGen has a 1 year low of $4.50 and a 1 year high of $21.94.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroGen in a research note on Wednesday, October 8th. Wall Street Zen upgraded FibroGen from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Finally, HC Wainwright reissued a “buy” rating and set a $43.00 target price on shares of FibroGen in a research report on Wednesday, September 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $43.00.

Institutional Trading of FibroGen

An institutional investor recently raised its position in FibroGen stock. Vanguard Group Inc. boosted its position in shares of FibroGen, Inc (NASDAQ:FGEN) by 3.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 184,244 shares of the biopharmaceutical company’s stock after acquiring an additional 6,204 shares during the period. Vanguard Group Inc. owned 4.56% of FibroGen worth $2,257,000 at the end of the most recent quarter. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.